HOMEBLOGMY LISTSMARKET NEWSEARNINGS CALENDARMARKET STATUS
STOCKSETFSINDEXESOPTIONSBONDSCURRENCIESCRYPTOCOMMODITIESMUTUAL FUNDSINTEREST RATESMACRO INDICATORSINVESTOR BASE
SETTINGS
Unicycive Therapeutics, Inc. (UNCY)
$3.49-0.25-6.68%Nov 2
Loading chart…
USA›Health Care›Biotechnology›Biotechnology
M.Cap$96M
Dividends—
Next report11 Nov, before open
Forecast
Target
P/E3.0
P/S0.25
P/B1.79
5-y avg sales growth+0.0%
Debt / EBITDA0.00
ROE—
Altman Z-score-1.99 (distress)
RSI44
MFI35
Price / MA50-22.4% (low) ↓
Trend pattern
News
Oct 27 · GlobeNewswire: UNCY URGENT DEADLINE: Unicycive Therapeutics, Inc. Investors Have Until November 2nd to Contact Bragar Eagel & Squire, P.C. Seeking Lead Plaintiff Role
Sep 29 · GlobeNewswire: Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
Sep 29 · PR Newswire: UNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit
Financial Statements
No data available
Team
Loading…
Leadership Changes
No changes found
Insider Activity
Loading…
DateTypeDescription
Loading…
Earnings Transcripts
Loading…
Dividends
Loading…
Investor Presentations
Loading…
Options
Expiration from:
to:
Strike from:
to:
Loading options…
Loading bonds…
Stress Test
Loading…
About

Unicycive Therapeutics is a US-based biotech company that focuses on developing innovative therapies for kidney diseases. The company's flagship products include Renazorb and UNI 494 which target hyperphosphatemia in chronic kidney disease patients and acute kidney injury, respectively. Established in 2016, the company is headquartered in Los Altos, California.

https://www.unicycive.com
Beta 0.00